Peptide inhibitors targeting the TANGO1-cTAGE5 interaction reduced collagen secretion from cells and decreased scarring in zebrafish wound healing.
Secretion machinery targetedInstead of blocking individual collagen types, these peptides target the cellular export system that all collagens use
What the researchers found
The peptide inhibitors specifically target the primary binding interface between TANGO1 and cTAGE5, two proteins required for collagen export from the endoplasmic reticulum. Treatment reduced protein levels of both TANGO1 and cTAGE5, blocking the secretion of multiple extracellular matrix components including collagens, fibrillin, and fibronectin.
In zebrafish, the peptide inhibitors altered tissue architecture and reduced granulation tissue formation during wound healing. In human dermal fibroblasts and cells from scleroderma patients (who have generalized fibrosis), the inhibitors reduced secretion of ECM proteins.
Why it matters
Fibrotic diseases (lung fibrosis, liver cirrhosis, scleroderma, keloid scars) affect millions and have few effective treatments. Rather than targeting individual collagen types, this approach blocks the export machinery that all large ECM proteins share. This could be a broad-spectrum anti-fibrotic strategy.
The numbers in context
- Reduced TANGO1 and cTAGE5 protein levels
- Inhibited secretion of collagens, fibrillin, and fibronectin
- Reduced granulation tissue in zebrafish wound healing
- Effective in human dermal fibroblasts and scleroderma patient cells
How the study worked
Researchers designed membrane-permeant peptide inhibitors targeting the TANGO1-cTAGE5 binding interface. They tested the peptides in cell culture (human dermal fibroblasts and scleroderma patient cells), measuring secretion of ECM proteins. In vivo testing used zebrafish cutaneous wound healing models to assess granulation tissue formation.
Who was studied
Human dermal fibroblasts, scleroderma patient cells, and zebrafish wound healing models
What this study cannot tell us
The in vivo data is from zebrafish, not mammals. Zebrafish wound healing differs from human scarring. The peptide inhibitors block secretion of multiple ECM proteins, not just collagen, which could cause off-target effects on normal tissue maintenance. Long-term safety of reducing ECM secretion is unknown. The peptides are membrane-permeant, but delivery to deep tissues in mammals would need optimization.
How to read the evidence
Rated preliminary: proof-of-concept study in cell culture and zebrafish. Needs mammalian in vivo testing.
When this study was published
Published in 2024. A novel therapeutic approach for fibrosis that is still in early development.
The bigger picture
Fibrotic diseases (lung fibrosis, liver cirrhosis, keloid scars) affect millions with few treatments. Rather than targeting individual collagen types, this approach blocks the secretion machinery itself — potentially stopping all excessive collagen production.
Questions still open
- Would blocking collagen secretion cause problems in normal wound healing?
- Can this approach be tested in mammalian fibrosis models?
Common questions
Can we prevent excessive scarring?
What diseases could this treat?
Read the original research
TANGO1 inhibitors reduce collagen secretion and limit tissue scarring.
Nature communications, 15(1), 3302
Citation
Raote, Ishier; Rosendahl, Ann-Helen; Häkkinen, Hanna-Maria; Vibe, Carina; Küçükaylak, Ismail; Sawant, Mugdha; Keufgens, Lena; Frommelt, Pia; Halwas, Kai; Broadbent, Katrina; Cunquero, Marina; Castro, Gustavo; Villemeur, Marie; Nüchel, Julian; Bornikoel, Anna; Dam, Binita; Zirmire, Ravindra K; Kiran, Ravi; Carolis, Carlo; Andilla, Jordi; Loza-Alvarez, Pablo; Ruprecht, Verena; Jamora, Colin; Campelo, Felix; Krüger, Marcus; Hammerschmidt, Matthias; Eckes, Beate; Neundorf, Ines; Krieg, Thomas; Malhotra, Vivek. (2024). TANGO1 inhibitors reduce collagen secretion and limit tissue scarring.. Nature communications, 15(1), 3302. https://doi.org/10.1038/s41467-024-47004-1